PeptideStack
5.2kquestions
20kanswers
220users

Is ecnoglutide at 8 mg/mL stable enough for ten weeks of multi-withdrawal use?

Asked 16 Aug 2025Modified 9 months agoViewed 11k times
23

Conditions: ecnoglutide · 8 mg/mL · ten weeks.

The claim is plausible, which is exactly why I want to check it.

I am able to read a paper if someone points me at one.

Can anyone point me at a primary source, or confirm that there is not one?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
bacteriostatic-water
bacteriostatic-water

Water for injection containing roughly 0.9 per cent benzyl alcohol as a bacteriostatic agent. It suppresses growth in a multiple-withdrawal vial;…

149 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
ecnoglutide
ecnoglutide

A long-acting GLP-1 receptor agonist with a cAMP-biased signalling profile. A niche tag, mostly used for mechanism questions about biased agonism…

223 questions
shareeditfollowflag
DV
askeddead_volume56k4816 Aug 2025

2 Answers

Sorted by votes
62

ten weeks is 70 days and, on a weekly schedule, 10 stopper punctures out of one vial at 8 mg/mL. Set the chemical question aside for a moment, because the puncture count is the one with a convention attached: 70 days is 2.5 times the twenty-eight days conventionally allowed for a preserved multi-dose preparation once it has been entered. Chemically, 8 mg/mL is high enough that adsorption to the glass is a rounding error and low enough that it is not protecting you from anything. What 10 withdrawals do add is 10 opportunities to introduce air, 10 coring events on the same stopper, and a headspace that grows with every draw — none of which show up on a certificate and all of which are avoided by splitting into aliquots at reconstitution.

The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

shareimprove this answerflag
BB
answeredbac_or_bust33k13726 Oct 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
41

Specifically, this is answerable from the chemistry rather than from anecdote, which is unusual and welcome.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

Sequence determines which pathways apply, so general statements are general.

Sequence decides which pathways are even available. Check the residues.

shareimprove this answerflag
LQ
answeredlipid_panel_q36k1276 Nov 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.